Table 1 demographic characteristics of the included studies
From: Prophylactic use of vancomycin powder on postoperative infection after total joint arthroplasty
Author ( Year) | Patients Size | Study design | Level of Evidence | Quality (RoB) | Dose (grams) | Follow up (months) | Main outcome |
|---|---|---|---|---|---|---|---|
Abuzaiter 2023 | 165 | RCT | II | 5 | 1 | 12 | Incidence of SSI |
Aljuhani 2021 | 96 | Retrospective | III | 6 | 2 | 24 | Incidence of SSI |
Assor 2009 | 135 | Retrospective | III | 6 | 1 | 24 | Incidence of SSI |
Cohen A 2018 | 1502 | Retrospective | III | 7 | 1 | 24 | Incidence of SSI |
Cohen E 2019 | 555 | Retrospective | III | 7 | 1 | 18 | Incidence of SSI |
Crawford D2018 | 1885 | Retrospective | III | 6 | 1 | 12 | Incidence of SSI |
Dial 2018 | 265 | Retrospective | III | 6 | 1 | 8 | Incidence of SSI |
Duan 2022 | 2725 | Retrospective | III | 7 | 2 | 3 | Incidence of SSI |
Erken 2020 | 93 | Retrospective | III | 7 | 1 | 12 | Incidence of SSI |
Hanada 2019 | 166 | Retrospective | III | 6 | 1 | 12 | Incidence of SSI |
Khatri 2017 | 115 | Retrospective | III | 6 | 1 | 6 | Incidence of SSI |
Koutalos 2020 | 290 | Retrospective | III | 7 | 2 | 24 | Incidence of SSI |
Matziolis2020 | 8945 | Retrospective | III | 6 | 1 | 12 | Incidence of SSI |
Otte 2017 | 1640 | Retrospective | III | 7 | 1 | 12 | Incidence of SSI |
Patel 2018 | 460 | Retrospective | III | 6 | 1 | 12 | Incidence of SSI |
Riesgo 2018 | 74 | Retrospective | III | 7 | 1 | 12 | Incidence of SSI |
Tahmaseb 2021 | 2024 | Retrospective | II | 7 | 1 | 12 | Incidence of SSI |
Wang 2023 | 90 | RCT | II | 3 | 0.5-1 | 3 | Incidence of SSI |
Winkler 2018 | 744 | Retrospective | III | 6 | 2 | 24 | Incidence of SSI |
Wu 2022 | 90 | RCT | II | 3 | 0.5-1 | 3 | Incidence of SSI |
Xu 2020 | 855 | Retrospective | III | 6 | 1 | 12 | Incidence of SSI |
Yavuz 2019 | 976 | Retrospective | III | 6 | 1 | 24 | Incidence of SSI |